Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat

Eva Hellström-Lindberg, MD, PhD, Karolinska University Hospital Huddinge, Stockholm, Sweden, outlines potential therapeutic options for patients with myelodysplastic syndromes (MDS) who have failed first-line treatment with erythropoiesis-stimulating agents (ESAs). The timing of ESA treatment is highly consequential for treatment response, with implementation prior to the onset of transfusion dependency resulting in a response rate twice as high as that seen in ESA-treated patients who are already transfusion-dependent. Prof. Hellström-Lindberg comments on luspatercept as a promising option for SF3B1-mutated MDS and highlights that imetelstat is also showing encouraging results in ongoing investigations. This interview took place at the European School of Hematology 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) in Budapest, Hungary.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

• #education
• #speaker_eva_hellstrm_lindberg
• #institution_karolinska_university_hospital_huddinge
• #event_esh_mds_2024
• #format_interview
• #subject_myelodysplastic_syndromes
• #field_treatment
• #field_disease_biology
• #field_perspectives
• #medicines_luspatercept
• #medicines_imetelstat
• #medicines_lenalidomide
• #medicines_azacitidine
• #erythropoiesis_stimulating_agents
• #esa_failure
• #transfusion_dependency
• #mds